Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy

Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of multiple myeloma (MM). It seems to determine cardiovascular toxicity, primarily arterial hypertension. No predictive factors for cardiovascular adverse events (CVAEs) are known in patients affected by multiple myel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Giulia, Bringhen, Sara, Maffei, Ilaria, Iannaccone, Andrea, Crea, Teresa, Ravera, Agnese, Astarita, Anna, Vallelonga, Fabrizio, Salvini, Marco, Gay, Francesca, Veglio, Franco, Milan, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562621/
https://www.ncbi.nlm.nih.gov/pubmed/31058856
http://dx.doi.org/10.3390/cancers11050622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562621/
https://www.ncbi.nlm.nih.gov/pubmed/31058856
http://dx.doi.org/10.3390/cancers11050622

Ejemplares similares